Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract
Documentation of Efficacy for Intralymphatic Allergen Immunotherapy in a Phase III Randomized, Parallel Group, Double Blind Placebo-controlled Multisite Field Trial
Sponsor: University of Aarhus
This PHASE1/PHASE2 trial investigates Allergic Asthma and Allergic Rhinitis and is currently completed. University of Aarhus leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Aarhus
- University of Zurich
For direct contact, visit the study record on ClinicalTrials.gov .